ADVA-OPTICAL
9.12.2020 09:02:14 CET | Business Wire | Press release
ADVA (FSE: ADV) and Advantech (TWSE: 2395.TW) today announced a joint test-drive portal initiative for remote evaluation of SD-WAN and security solutions on universal CPE (uCPE). Based on the ADVA’s Ensemble suite of network functions virtualization (NFV) technology and Advantech edge appliances, the joint remote lab will streamline the evaluation process for network engineers and architects working remotely by providing them with free access to a wide range of pre-integrated SD-WAN uCPE platforms. The initiative will help communication service providers (CSPs) to overcome the challenges of remote evaluation, such as lab licensing and device shipping to distributed teams.
“We’ve joined forces with ADVA during these challenging times to help network engineers and architects working from home rapidly evaluate different SD-WAN, security and enterprise edge solutions through an open uCPE lab that is fully supported by a team of network experts,” said James Yang, VP, cloud IoT group, Advantech. “This is the first in a series of joint initiatives that will grow our partnership stronger with the objective of delivering hassle-free open uCPE solutions to market that accelerate time to revenue, minimize supply chain risks and support disaggregated SD-WAN strategies toward next-generation converged and cloud-native architectures.”
The new uCPE test-drive portal is built on the ADVA Ensemble open virtualization suite, including carrier-class management and orchestration, and virtual network functions (VNFs) hosting capabilities. Lab users will be provided access to Advantech FWA-1112VC edge appliances hosting the ADVA Ensemble software and will be able to test Fortinet’s Secure SD-WAN solution that enables a security-driven networking approach and the Silver Peak Unity EdgeConnect™ SD-WAN edge platform that provides automated integration with cloud-delivered security services. The Advantech FWA-1112VC platform features Intel Atom® processors that have been cost-optimized for volume deployment and provide flexible connectivity options including 5G, Wi-Fi 6 and 10GbE. Encryption and compression acceleration improvements can be assessed using Intel® QuickAssist with DPDK. Other partner VNFs and Advantech hardware platforms are available for evaluation under request.
“By partnering with Advantech, we’re helping to simplify the virtualization journey for operators and enterprises. This is especially crucial right now with so many CSP and enterprise engineers operating from home. Our joint virtual lab gives those working remotely the ability to see a complete solution and evaluate functionality and performance without having to set it up in their own labs,” said Mike Heffner, VP, product line management, Edge Cloud, ADVA. “Together with Advantech, we’re eliminating the pain of integration and helping our customers realize the benefits of multi-vendor uCPE. This test-drive portal initiative is also key to accelerating the shift towards fully cloud-native architectures.”
Further details on the uCPE test-drive portal are available here: https://adva.li/ucpe-test-drive-portal .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005023/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom